Ohio Public Employees Retirement System (OPERS)’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.29M Buy
96,968
+12,900
+15% +$430K 0.01% 859
2026
Q1
$2.53M Buy
84,068
+7,000
+9% +$225K 0.01% 975
2025
Q4
$2.41M Sell
77,068
-6,400
-8% -$158K 0.01% 1022
2025
Q3
$1.69M Buy
83,468
+4,200
+5% +$73.8K 0.01% 1184
2025
Q2
$1.33M Sell
79,268
-24,300
-23% -$392K ﹤0.01% 1254
2025
Q1
$1.59M Buy
+103,568
New +$1.85M 0.01% 1171
2024
Q4
Sell
-207,085
Closed -$3.73M 2411
2024
Q3
$3.73M Buy
+207,085
New +$3.62M 0.02% 783

Other funds holding TEVA

Ohio Public Employees Retirement System (OPERS)'s TEVA Position: Q2 2026 in Review

Ohio Public Employees Retirement System (OPERS) increased its Teva Pharmaceuticals (TEVA) stake by 15% in Q2 2026, buying an estimated $430K and bringing the position to 96,968 shares worth $3.29M. The position accounts for 0.01% of the portfolio, ranked #859.

Ohio Public Employees Retirement System (OPERS) first reported a position in TEVA in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.73M in Q3 2024. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Ohio Public Employees Retirement System (OPERS) held 96,968 shares of Teva Pharmaceuticals worth $3.29M as of Q2 2026.
  • Ohio Public Employees Retirement System (OPERS) bought 12,900 Teva Pharmaceuticals shares in Q2 2026, an estimated $430K.
  • Teva Pharmaceuticals made up 0.01% of Ohio Public Employees Retirement System (OPERS)'s portfolio in Q2 2026, its #859 holding.
  • Ohio Public Employees Retirement System (OPERS) first reported a position in Teva Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Ohio Public Employees Retirement System (OPERS)'s Teva Pharmaceuticals position peaked at $3.73M in Q3 2024.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Ohio Public Employees Retirement System (OPERS)'s 13F filing for Q2 2026, filed 17 Aug 2026.